Printer Friendly

Seres Therapeutics Eyes USD 60m Raise in Public Stock Offering.

M2 PHARMA-June 17, 2019-Seres Therapeutics Eyes USD 60m Raise in Public Stock Offering

(C)2019 M2 COMMUNICATIONS

- US-based microbiome therapeutics platform company Seres Therapeutics, Inc. (NASDAQ: MCRB) is commencing an underwritten registered public offering of USD 60m of shares of its common stock, the company said.

As part of this offering, Seres intends to grant the underwriters a 30-day option to purchase up to an additional USD 9m of shares of its common stock. All of the shares in the proposed offering are to be sold by Seres.

Goldman Sachs and Co. LLC and Cowen and company, LLC are acting as joint book-running managers for the offering.

The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 17, 2019
Words:154
Previous Article:Tetraphase Pharmaceuticals Launches Corporate Reorganisation.
Next Article:Savara's IMPALA Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis Fails to Meet Primary Endpoint.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters